MedTrace Logo

Effect of Low-dose Esketamine on Postoperative Depression in Patients With Breast Cancer

NCT04850937 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2022-07-28

No results posted yet for this study

Summary

esketamine is an optical isomer of ketamine. Compared with ketamine, esketamine has the characteristics of higher effective value, stronger receptor affinity, less adverse reactions of nervous system, and pharmacokinetics is controllable.

Domestic and foreign studies have focused on the therapeutic effect of esketamine on major depression, but less attention has been paid to perioperative depression.This study intends to explore the effect of small doses of esketamine on patients with breast cancer.Postoperative depression and pain are observed.

Conditions

Interventions

DRUG

Esketamine

The experimental group will be given 0.25mg/kg esketamine slowly intravenously after anesthesia induction

DRUG

normal saline

The experimental group will be given 0.5ml/kg normal saline intravenously after anesthesia induction

Sponsors & Collaborators

  • Yangzhou University

    lead OTHER

Principal Investigators

  • LIU M YU · Yangzhou University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-10
Primary Completion
2021-04-10
Completion
2022-05-10

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04850937 on ClinicalTrials.gov